The impact of copper status on lubabegron fumarate-induced growth and adipose immune cell infiltration in beef feedlot steers
Henderson JA., McGill JL., Hansen SL.
Animal Study with a reported sample of 12, published in J Anim Sci (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Anim Sci (2026)
- Reported sample size
- 12
- Source database
- Europe PMC
- PMID
- 41706733
- PMCID
- PMC12989106
- DOI
- 10.1093/jas/skag047
Abstract (original English)
The objective of this study was to evaluate the effect of copper (Cu) status on response to lubabegron fumarate (LUB; Experior, Elanco, Greenfield, IN) and adipose tissue physiology. Forty-eight Angus crossbred steers (469 ± 31 kg) were enrolled in a 77-day finishing study, housed in pens of six, with a GrowSafe bunk (GrowSafe Systems, Ltd, Airdrie, AB, Canada) in each pen and implanted (Revalor-200, Merck Animal Health, Madison, NJ; 200 mg TBA + 20 mg E2) on day 0. A 2 × 2 factorial arrangement was applied to Cu status (Cu0, no supplemental Cu; or Cu10, 10 mg supplemental Cu/kg DM as CuSO4) and LUB (36 mg/steer/day, LUB; or no LUB, NOLUB). A prior trial resulted in steers with distinct liver Cu (Cu0 and Cu10 were 42 ± 21 and 193 ± 31 mg Cu/kg DM, respectively). Lubabegron was fed from day 37 to day 73, and cattle harvested on day 78. Weights were collected on days -1, 0, 37, 55 (mid-Experior), 76, and 77. Blood was collected on days 0, 37, 55, and 76 for non-esterified fatty acids (NEFA), glucose, and insulin. Subcutaneous adipose biopsies were collected on days 0, 37, and 66. Data were analyzed using the MIXED procedure of SAS as a factorial design, with steer as the experimental unit (n = 12 per treatment). From days 0-37, Cu0 daily gain and feed efficiency (G: F) were greater than Cu10 (P < 0.01). Overall DMI was greater in Cu10 than Cu0 (P = 0.04) and not affected by LUB (
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.